This content is for informational purposes only and is not a substitute for professional advice.
Nootropics are not one addiction-risk category. A caffeine capsule, a bacopa extract, a prescription stimulant, and a gray-market sedative can all be sold into the same conversation, which is why serious risk checks matter more than the word nootropic.
The safer question is whether a compound can create reinforcement, tolerance, withdrawal, dose escalation, loss of control, or harm despite continued use. Those signals can appear with legal products, prescription medications, and unapproved substances.
Decision criteria
This guide scores risk by pharmacology, withdrawal reports, dose escalation pressure, legal status, and the penalty for abrupt discontinuation. It is educational, not a diagnosis. If use feels hard to stop, causes impairment, or has become tied to work identity, clinician review is warranted.
| Category | Typical examples | Dependence concern | Practical rule |
|---|---|---|---|
| Common stimulants | Caffeine, nicotine | Tolerance and withdrawal are plausible | Set a ceiling and caffeine cutoff |
| Prescription stimulants | Amphetamine, methylphenidate | Medical supervision is required | Use only as prescribed |
| Sedating gray-market agents | Phenibut, tianeptine where sold as supplement | High withdrawal and escalation concern | Avoid casual self-experimentation |
| Classic dietary nootropics | Bacopa, creatine, citicoline, theanine | Lower addiction signal | Still log adverse effects and stop rules |
| Mood-active supplements | 5-HTP, kava, rhodiola | Interaction and state-change concern | Screen medications first |
What addiction means here
Addiction is not the same as liking a supplement. It involves impaired control, compulsive use, craving, continued use despite harm, and functional cost. Dependence means the body adapts enough that stopping can produce symptoms. Tolerance means the same dose produces less effect.
Caffeine illustrates the distinction. Many people can use it without addiction, yet dependence and withdrawal symptoms such as headache, fatigue, low mood, and irritability are documented. Nicotine has a stronger reinforcement profile. Prescription stimulants can be appropriate under medical care and risky outside it.
Red flags
Treat these as stop-and-review signals: raising the dose to feel normal, using despite insomnia or anxiety, hiding use, mixing with alcohol or sedatives, using to offset another substance, ordering from unclear suppliers, or feeling unable to work without it.
For phenibut, tianeptine, kratom, high-dose caffeine powders, and research-chemical stimulants, risk-first advice is simple: do not treat internet availability as evidence of safety.
Safer testing protocol
| Step | Action | Reason |
|---|---|---|
| Baseline | Log sleep, mood, anxiety, and output for 7 days | Separates need from novelty |
| Single variable | Test one compound at a conservative dose | Keeps attribution possible |
| Ceiling | Set a maximum dose before starting | Blocks escalation logic |
| Stop rule | Stop for insomnia, panic, chest pain, compulsive use, or risky mixing | Moves safety ahead of productivity |
| Review | Reassess after 2 to 4 weeks | Prevents indefinite drift |
Disclosure
Unfair can help structure logs, dose ceilings, and stop rules. It cannot determine whether a pattern is addiction, diagnose ADHD, or replace medical care. The app is not a safeguard against unsafe sourcing, misuse, or medication interactions.
References
Juliano LM, Griffiths RR. A critical review of caffeine withdrawal. Psychopharmacology. 2004. https://pubmed.ncbi.nlm.nih.gov/15448977/
↩U.S. Food and Drug Administration. Spilling the Beans: How Much Caffeine is Too Much? https://www.fda.gov/consumers/consumer-updates/spilling-beans-how-much-caffeine-too-much
↩National Institute on Drug Abuse. Drug Misuse and Addiction. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction
↩Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal. BMJ Case Reports. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6535394/
↩